As of 2025-05-15, the Intrinsic Value of Benitec Biopharma Inc (BNTC) is -4.19 USD. This BNTC valuation is based on the model Peter Lynch Fair Value. With the current market price of 13.58 USD, the upside of Benitec Biopharma Inc is -130.86%.
Based on its market price of 13.58 USD and our intrinsic valuation, Benitec Biopharma Inc (BNTC) is overvalued by 130.86%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.19 - -4.19 | -4.19 | -130.86% |
| P/E | (4.24) - (8.23) | (5.95) | -143.8% |
| DDM - Stable | (7.25) - (27.46) | (17.36) | -227.8% |
| DDM - Multi | (6.75) - (20.33) | (10.19) | -175.0% |
| Market Cap (mil) | 346.97 |
| Beta | 0.63 |
| Outstanding shares (mil) | 25.55 |
| Enterprise Value (mil) | 268.69 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.42% |
| Cost of Debt | 5.00% |
| WACC | 6.54% |